UNSPSC 51291711: Desvenlafaxine succinate

This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZB22ENF0XR. European Medicines Agency schedules Desvenlafaxine succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27750. Desvenlafaxine succinate generally arises in the molecular formula C16H25NO2.C4H6O4.H2O. The term 'desvenlafaxine succinate' is a United States Adopted Name designation.

Most nations, for tariff and trade purposes, schedule desvenlafaxine succinate under HS 29225000 and SITC 51467. As of Q4 2014, DESVENLAFAXINE SUCCINATE remains US FDA's Preferred Term for this commodity. Desvenlafaxine succinate bears US NLM identifiers UMLS ID C1871864 and NCI Concept Code C61704. SMILES: CN(C)CC(C1CCC(CC1)O)C2(CCCCC2)O.C(CC(=O)O)C(=O)O.O.

UNSPSC 51291711 Desvenlafaxine succinate is a Commodity code representing a specific pharmaceutical product — an antidepressant used in prescription medication regimens — but the recent state and local opportunities posted under this code do not reflect direct procurement of desvenlafaxine itself. Instead, Seminole County, Florida has solicited naloxone and drug deactivation systems through an IFB; Texas HHS issued an RFI exploring direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers. The code shows minimal recent activity aligned with its nominal scope, and the opportunities logged suggest that state and local procurement of specific pharmaceuticals like desvenlafaxine typically flows through cooperative purchasing agreements, pharmaceutical wholesaler channels, or health benefit procurement vehicles rather than as discrete commodity solicitations.

Activity under this code spans Seminole County (a Florida local health authority), the Texas Health and Human Services Commission (a state agency), and MMCAP (a multistate cooperative purchasing consortium with Minnesota administrative oversight). The Seminole County IFB, posted June 30, 2026 with a response deadline of July 26, 2023, and the Minnesota RFP for generic pharmaceuticals, posted January 20, 2026 with proposals due March 26, 2026, represent the only recent opportunities with defined solicitation processes. The Texas RFI of April 3, 2026 functions as preliminary market intelligence rather than a formal procurement action. Geographic concentration is limited; the source identifies activity in Florida, Texas, and Minnesota, with no other jurisdictions represented. The mismatch between the code's nominal product and actual recent solicitations reflects how state and local pharmaceutical procurement often bypasses individual NDC-level codes in favor of broader procurement vehicles and cooperative arrangements with established wholesaler networks.